Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Share-based Compensation (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Share-based Compensation for 9 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 7.71% year-over-year to $1.6 million, compared with a TTM value of $6.9 million through Dec 2025, down 15.78%, and an annual FY2025 reading of $6.9 million, down 15.78% over the prior year.
  • Share-based Compensation was $1.6 million for Q4 2025 at Puma Biotechnology, down from $1.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $18.2 million in Q2 2021 and bottomed at -$14.8 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $2.5 million, with a median of $2.4 million recorded in 2023.
  • The sharpest move saw Share-based Compensation tumbled 256.03% in 2021, then surged 117.78% in 2022.
  • Year by year, Share-based Compensation stood at -$14.8 million in 2021, then soared by 117.78% to $2.6 million in 2022, then decreased by 7.46% to $2.4 million in 2023, then decreased by 27.96% to $1.8 million in 2024, then dropped by 7.71% to $1.6 million in 2025.
  • Business Quant data shows Share-based Compensation for PBYI at $1.6 million in Q4 2025, $1.7 million in Q3 2025, and $1.6 million in Q2 2025.